BACKGROUND: Men with germline BRCA1/2 mutations are not well studied compared to their female counterparts. This study evaluates the cancer characteristics, family history of cancer, and outcomes of male BRCA1/2 mutation carriers. METHODS: All men with germline BRCA1/2 mutations who attended genetic assessment between October 1995 and October 2019 at the Medical University of Vienna were identified. Clinicohistopathological features, family history of cancer, and outcomes were assessed by mutation status. RESULTS: Of the 323 men included, 45 (13.9%) had a primary cancer diagnosis, many of whom were BRCA2 carriers (75.5%). Breast cancer (BC) was the most common cancer (57.8%) followed by prostate cancer (15.6%). Invasive ductal carcinoma and hormone receptor positive tumors were the most common. Among 26 BC-affected patients, 42% did not have any relatives with cancer. Parent of origin was only known in half of the 26 men, with 42% of them inherited through the maternal lineage versus 8% through the paternal. BRCA2 carriers and those with a family history of BC had worse overall survival (20 y vs. 23 y BRCA1 carriers; P = 0.007; 19 y vs. 21 y for those without family history of BC; P = 0.036). CONCLUSION: Male BRCA2 carriers were most likely to develop cancer and had worse prognosis. In our dataset, BC was the most common cancer, likely due to referral bias. Not all mutation carriers present with BC or have a family history of cancer to warrant genetic testing.

Department of Obstetrics Gynecology and Comprehensive Cancer Center Medical University of Vienna Waehringer Guertel 18 20 1090 Vienna Austria

Department of Urology 2nd Faculty of Medicine Charles University 15006 Prague Czech Republic

Department of Urology Medical University of Vienna Waeringer Guertel 18 20 1090 Vienna Austria

Department of Urology University of Texas Southwestern Dallas TX 75390 USA

Department of Urology Weill Cornell Medical College New York NY 10065 USA

Institute for Urology and Reproductive Health Sechenov University 119991 Moscow Russia

Zobrazit více v PubMed

Cancer risks in BRCA2 mutation carriers. J. Natl. Cancer Inst. 1999;91:1310–1316. doi: 10.1093/jnci/91.15.1310. PubMed DOI

Ford D., Easton D.F., Bishop D.T., Narod S.A., Goldgar D.E. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet. 1994;343:692–695. doi: 10.1016/S0140-6736(94)91578-4. PubMed DOI

Kuchenbaecker K.B., Hopper J.L., Barnes D., Phillips K.-A., Mooij T.M., Roos-Blom M.-J., Jervis S., Van Leeuwen F.E., Milne R.L., Andrieu N., et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017;317:2402–2416. doi: 10.1001/jama.2017.7112. PubMed DOI

Ibrahim M., Yadav S., Ogunleye F., Zakalik D. Male BRCA mutation carriers: Clinical characteristics and cancer spectrum. BMC Cancer. 2018;18:179. doi: 10.1186/s12885-018-4098-y. PubMed DOI PMC

Silvestri V., Leslie G., Barnes D.R., Agnarsson B.A., Aittomäki K., Alducci E., Andrulis I.L., Barkardottir R.B., Barroso A., Barrowdale D., et al. Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) JAMA Oncol. 2020;6:1218–1230. doi: 10.1001/jamaoncol.2020.2134. PubMed DOI PMC

Golan T., Raitses-Gurevich M., Kelley R.K., Bocobo A.G., Borgida A., Shroff R.T., Holter S., Gallinger S., Ahn D.H., Aderka D., et al. Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study. Oncologist. 2017;22:804–810. doi: 10.1634/theoncologist.2016-0415. PubMed DOI PMC

Key Statistics for Breast Cancer in Men American Cancer Society. [(accessed on 18 February 2021)]. Available online: https://www.cancer.org/cancer/breast-cancer-in-men/about/key-statistics.html.

Tai Y.C., Domchek S., Parmigiani G., Chen S. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J. Natl. Cancer Inst. 2007;99:1811–1814. doi: 10.1093/jnci/djm203. PubMed DOI PMC

Noone A.M., Howlader N., Krapcho M. SEER Cancer Statistics Review (CSR) 1975–2015. [(accessed on 15 June 2021)]; Available online: https://seer.cancer.gov/archive/csr/1975_2015/

Konduri S., Singh M., Bobustuc G., Rovin R., Kassam A. Epidemiology of male breast cancer. Breast. 2020;54:8–14. doi: 10.1016/j.breast.2020.08.010. PubMed DOI PMC

Daly M.B., Pal T., Berry M.P., Buys S.S., Dickson P., Domchek S.M., Elkhanany A., Friedman S., Goggins M., Hutton M.L., et al. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc. Netw. 2021;19:77–102. doi: 10.6004/jnccn.2021.0001. PubMed DOI

Mahon S.M. Cancer risks for men with BRCA1/2 mutations. Oncol. Nurs. Forum. 2014;41:99–101. doi: 10.1188/14.ONF.99-101. PubMed DOI

Petrucelli N., Daly M.B., Pal T. BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer. In: Adam M.P., Ardinger H.H., Pagon R.A., Wallace S.E., Bean L.J.H., Mirzaa G., Amemiya A., editors. GeneReviews(®) University of Washington; Seattle, WA, USA: 1993. PubMed

Moran A., O’Hara C., Khan S., Shack L., Woodward E., Maher E.R., Lalloo F., Evans D.G. Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. Fam. Cancer. 2012;11:235–242. doi: 10.1007/s10689-011-9506-2. PubMed DOI

Oh M., Alkhushaym N., Fallatah S., Althagafi A., Aljadeed R., Alsowaida Y., Jeter J., Martin J.R., Babiker H.M., McBride A., et al. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis. Prostate. 2019;79:880–895. doi: 10.1002/pros.23795. PubMed DOI

Silvestri V., Barrowdale D., Mulligan A.M., Neuhausen S.L., Fox S., Karlan B.Y., Mitchell G., James P., Thull D.L., Zorn K.K., et al. Male breast cancer in BRCA1 and BRCA2 mutation carriers: Pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res. 2016;18:15. doi: 10.1186/s13058-016-0671-y. PubMed DOI PMC

Sun P., Li Y., Chao X., Li J., Luo R., Li M., He J. Clinical characteristics and prognostic implications of BRCA-associated tumors in males: A pan-tumor survey. BMC Cancer. 2020;20:994. doi: 10.1186/s12885-020-07481-1. PubMed DOI PMC

André S., Pereira T., Silva F., Machado P., Vaz F., Aparício M., Silva G.L., Pinto A.E. Male breast cancer: Specific biological characteristics and survival in a Portuguese cohort. Mol. Clin. Oncol. 2019;10:644–654. doi: 10.3892/mco.2019.1841. PubMed DOI PMC

Castro E., Goh C., Olmos D., Saunders E., Leongamornlert D., Tymrakiewicz M., Mahmud N., Dadaev T., Govindasami K., Guy M., et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J. Clin. Oncol. 2013;31:1748–1757. doi: 10.1200/JCO.2012.43.1882. PubMed DOI PMC

Ottini L., Silvestri V., Rizzolo P., Falchetti M., Zanna I., Saieva C., Masala G., Bianchi S., Manoukian S., Barile M., et al. Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients: Results from a collaborative multicenter study in Italy. Breast Cancer Res. Treat. 2012;134:411–418. doi: 10.1007/s10549-012-2062-0. PubMed DOI

Childers K.K., Maggard-Gibbons M., Macinko J., Childers C.P. National Distribution of Cancer Genetic Testing in the United States: Evidence for a Gender Disparity in Hereditary Breast and Ovarian Cancer. JAMA Oncol. 2018;4:876–879. doi: 10.1001/jamaoncol.2018.0340. PubMed DOI PMC

Hesse-Biber S., Dwyer A.A., Yi S. Parent of origin differences in psychosocial burden and approach to BRCA risk management. Breast J. 2020;26:734–738. doi: 10.1111/tbj.13633. PubMed DOI

Plon S.E., Eccles D.M., Easton D., Foulkes W.D., Genuardi M., Greenblatt M.S., Hogervorst F.B., Hoogerbrugge N., Spurdle A.B., Tavtigian S.V. Sequence variant classification and reporting: Recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum. Mutat. 2008;29:1282–1291. doi: 10.1002/humu.20880. PubMed DOI PMC

Okano M., Nomizu T., Tachibana K., Nagatsuka M., Matsuzaki M., Katagata N., Ohtake T., Yokoyama S., Arai M., Nakamura S. The relationship between BRCA-associated breast cancer and age factors: An analysis of the Japanese HBOC consortium database. J. Hum. Genet. 2021;66:307–314. doi: 10.1038/s10038-020-00849-y. PubMed DOI PMC

Yadav S., Karam D., Bin Riaz I., Xie H., Durani U., Duma N., Giridhar K.V., Hieken T.J., Boughey J.C., Mutter R.W., et al. Male breast cancer in the United States: Treatment patterns and prognostic factors in the 21st century. Cancer. 2020;126:26–36. doi: 10.1002/cncr.32472. PubMed DOI PMC

Page E.C., Bancroft E.K., Brook M.N., Assel M., Hassan Al Battat M., Thomas S., Taylor N., Chamberlain A., Pope J., Raghallaigh H.N., et al. Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. Eur. Urol. 2019;76:831–842. doi: 10.1016/j.eururo.2019.08.019. PubMed DOI PMC

Gucalp A., Traina T.A., Eisner J.R., Parker J.S., Selitsky S.R., Park B.H., Elias A.D., Baskin-Bey E.S., Cardoso F. Male breast cancer: A disease distinct from female breast cancer. Breast Cancer Res. Treat. 2019;173:37–48. doi: 10.1007/s10549-018-4921-9. PubMed DOI PMC

Gargiulo P., Pensabene M., Milano M., Arpino G., Giuliano M., Forestieri V., Condello C., Lauria R., De Placido S. Long-term survival and BRCA status in male breast cancer: A retrospective single-center analysis. BMC Cancer. 2016;16:375. doi: 10.1186/s12885-016-2414-y. PubMed DOI PMC

Marabelli M., Calvello M., Bonanni B. Cancer: More genetic BRCA testing for men. Nature. 2019;573:346. doi: 10.1038/d41586-019-02775-2. PubMed DOI

Liede A., Metcalfe K., Hanna D., Hoodfar E., Snyder C., Durham C., Lynch H.T., Narod S.A. Evaluation of the needs of male carriers of mutations in BRCA1 or BRCA2 who have undergone genetic counseling. Am. J. Hum. Genet. 2000;67:1494–1504. doi: 10.1086/316907. PubMed DOI PMC

Evans D.G.R., Harkness E., Lalloo F. The BRCA1/2 Parent-of-Origin Effect on Breast Cancer Risk—Letter. Cancer Epidemiol. Biomark. Prev. 2017;26:284. doi: 10.1158/1055-9965.EPI-16-0832. PubMed DOI

Vos J.R., Oosterwijk J.C., Aalfs C.M., Rookus M.A., Adank M.A., van der Hout A.H., van Asperen C.J., Gómez Garcia E.B., Mensenkamp A.R., Jager A., et al. Bias Explains Most of the Parent-of-Origin Effect on Breast Cancer Risk in BRCA1/2 Mutation Carriers. Cancer Epidemiol. Biomark. Prev. 2016;25:1251–1258. doi: 10.1158/1055-9965.EPI-16-0182. PubMed DOI

Ozanne E.M., O’Connell A., Bouzan C., Bosinoff P., Rourke T., Dowd D., Drohan B., Millham F., Griffin P., Halpern E.F., et al. Bias in the reporting of family history: Implications for clinical care. J. Genet. Couns. 2012;21:547–556. doi: 10.1007/s10897-011-9470-x. PubMed DOI

Daly M.B., Montgomery S., Bingler R., Ruth K. Communicating genetic test results within the family: Is it lost in translation? A survey of relatives in the randomized six-step study. Fam. Cancer. 2016;15:697–706. doi: 10.1007/s10689-016-9889-1. PubMed DOI PMC

van den Broek A.J., Schmidt M.K., van ‘t Veer L.J., Tollenaar R.A., van Leeuwen F.E. Worse breast cancer prognosis of BRCA1/BRCA2 mutation carriers: What’s the evidence? A systematic review with meta-analysis. PLoS ONE. 2015;10:e0120189. doi: 10.1371/journal.pone.0120189. PubMed DOI PMC

Baretta Z., Mocellin S., Goldin E., Olopade O.I., Huo D. Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis. Medicine (Baltimore) 2016;95:e4975. doi: 10.1097/MD.0000000000004975. PubMed DOI PMC

Schmidt M.K., van den Broek A.J., Tollenaar R.A., Smit V.T., Westenend P.J., Brinkhuis M., Oosterhuis W.J., Wesseling J., Janssen-Heijnen M.L., Jobsen J.J., et al. Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women. J. Natl. Cancer Inst. 2017;109:djw329. doi: 10.1093/jnci/djw329. PubMed DOI